Subscribe To

Price Alert Latest News Economic Calendar News

EDSA / Edesa Biotech to Present Favorable Dermatitis Drug Results at American Academy of Dermatology Association Annual Meeting

TORONTO, ON / ACCESSWIRE / March 16, 2023 / Edesa Biotech, Inc. announced today that the company has been selected to present clinical trial data from a Phase 2B multi-dose study of its EB01 drug candidate at a Late Breaking Abstract session of the American Academy of Dermatology Association (AAD) annual meeting being held March 17-21, 2023. The presentation will detail the statistically significant topline results achieved by 1.0% EB01 cream in moderate-to-severe chronic allergic contact dermatitis (ACD) subjects, as well as data from other dose concentrations and safety data. Read More

Demo Live Account See Partner Details

Content Topics

Edesa

Biotech

Present

Favorable

Dermatitis

Drug

Results

American

Academy

Dermatology

Association

Annual

Meeting

Stock

EDSA

Posted: Mar 16 2023, 16:10

Author Name: Accesswire

EDSA News

By Accesswire
March 16, 2023

Edesa Biotech to Present Favorable Dermatitis Drug Results at American Academy of Dermatology Association Annual Meeting

TORONTO, ON / ACCESSWIRE / March 16, 2023 / Edesa Biotech, Inc. announced today that the company has been selected to present clinical trial data from

By Seeking Alpha
April 18, 2022

Edesa Biotech: Leader In Developing Treatments For COVID-19 And ACD

Edesa is one of 4 pharmaceutical companies that received a grant from the Canadian government to develop a drug to treat COVID-19. EB01 achieved all e

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.